Tobacco dependence. Global public health potential for new medications development and indications

Annals of the New York Academy of Sciences

Volumn 909, Issue , 2000, Pages 247-256

  Henningfield, Jack E ^a,b   Fant, Reginald V ^b   Gitchell, Joseph ^b   Shiffman, Saul ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PINNEY ASSOCIATES   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NEUROTRANSMITTER; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR;

CAUSE OF DEATH; CIGARETTE SMOKING; COMMERCIAL PHENOMENA; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DRUG INDUSTRY; DRUG LEGISLATION; ECONOMIC ASPECT; HUMAN; PATIENT ATTITUDE; PUBLIC HEALTH; SEIZURE; SUBSTITUTION THERAPY; TOBACCO; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

EID: 0033928457     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06686.x     Document Type: Conference Paper

References (37)

1. 1. MCGINNIS, J.M. & W.H. FOEGE. 1993. Actual causes of death in the United States. JAMA 270: 2207-2212.
2. 2. PETO, R., A.D. LOPEZ, J. BOREHAM, et al. 1994. Mortality from smoking in developed countries 1950-2000. Oxford University Press. Oxford.
3. 3. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. 1990. The Health Benefits of Smoking Cessation, A Report of the Surgeon General. U.S. Government Printing Office. Washington DC.
4. 4. WARNER, K.E., C.C. PECK, R.L. WOOSLEY & J.E. HENNINGFIELD. 1998. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease, Preface. Food Drug Law J. 53(S): 1-10.
5. 5. KOOP, C.E. 1997, March 8. Don't forget the smokers. The Washington Post: C7.
6. 6. HUGHES, J.R., M.G. GOLDSTEIN, R.D. HURT & S. SHIFFMAN. 1999. Recent advances in the pharmacotherapy of smoking. JAMA 281(1): 72-76.
7. 7. CENTERS FOR DISEASE CONTROL. 1997. Impact of promotion of the Great American Smokeout and availability of over-the-counter nicotine medications. MMWR 46: 867-871.
8. 8. SHIFFMAN, S., J. GITCHELL, J.M. PINNEY, et al. 1997. Public health benefit of over-the-counter nicotine medications. Tobacco Control 6: 306-310.
9. 9. HENNINGFIELD, J.E. & J. SLADE. 1998. Tobacco dependence medications: public health and regulatory issues. Food and Drug Law J. 53(suppl.): 75-114.
10. 10. PAGE, J.A. 1998. Federal regulation of tobacco products and products that treat tobacco dependence: are the playing fields level? Food and Drug Law J. 53(suppl.): 11-42.
11. 11. SLADE, J. & J.E. HENNINGFIELD. Tobacco product regulation: context and issues. Food and Drug Law J. 53(suppl.): 43-74.
12. 12. HWANG, S.L. & A.M. FREEDMAN. 1995. B.A.T. considered patches but stuck to making cigarettes. Wall Street Journal, October 9, 1995: B3.
13. 13. REUTER, B. Competitive analysis. Philip Morris.
14. 14. WlLKENFELD J., J.E. HENNINGFIELD, J. SLADE, D. BURNS & J. PINNEY. 2000. Its time for a change: cigarette smokers deserve meaningful information about the smoke they are inhaling. J. Natl. Cancer Inst. In press.
15. 15. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. 1996. Clinical Practice Guideline: Smoking Cessation. Agency for Health Care Policy and Research (AHCPR Publication No. 96-0692). Rockville, MD.
16. 16. BENOWITZ, N.L., H. PORCHET, L. SHEINER, et al. 1988. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 44: 23.
17. 17. SCHNEIDER, N.G., E. LUNELL, R.E. OLMSTEAD & K.O. FAGERSTROM. 1996. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin. Pharmacokinet. 31: 65.
18. 18. BENOWITZ, N.L. 1993. Nicotine replacement therapy: what has been accomplished -can we do better? Drugs 45: 157.
19. 19. HENNINGFIELD, J.E., J.M. STAPLETON, N.L. BENOWITZ, et al. 1993. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 33: 23-29.
20. 20. HUGHES, J.R., M.G. GOLDSTEIN, R.D. HURT & S. SHIFFMAN. 1999. Recent advances in the pharmacotherapy of smoking. JAMA 281: 72-76.
21. 21. HENNINGFIELD, J.E. 1995. Nicotine medications for smoking cessation. New Engl. J. Med. 333(18): 1196-1203.
22. 22. MEDICAL ECONOMICS INC. 1999. Physicians' Desk Reference, 53rd Edition. Medical Economics Company, Inc. Montvale, NJ.
23. 23. CROMWELL, J., W.J. BARTOSCH, M.C. FIORE, et al. 1997. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 278: 1759-1766.
24. 24. PARROTT, S., C. GODFREY, M. RAW, et al. 1998. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 53(Suppl. 5, Pt. 2): S1-S38.
25. 25. AMERICAN PSYCHIATRIC ASSOCIATION. 1994. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV, Fourth Edition. American Psychiatric Association. Washington, DC.
26. 26. HEISHMAN, S.J., R.C. TAYLOR & J.E. HENNINGFIELD. 1994. Nicotine and smoking: a review of the effects on human performance. Exp. Clin. Psychopharmacol. 2: 345-395.
27. 27. HENNINGFIELD, J.E., L.M. SCHUH & M.E. JARVIK. 1995. Pathophysiology of tobacco dependence. In Psychopharmacology: The Fourth Generation of Progress. F. Bloom & D.J. Kupfer, Eds. : 1715-1720. Raven Press. New York.
28. 28. KESSLER, D., A. WITT, P. BARNETT, et al. The Food and Drug Administration's Regulation of Tobacco Products. New Engl. J. Med. 335: 988-994.
29. 29. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. 1988. The Health Consequences of Smoking: Nicotine Addiction, A Report of the Surgeon General. U.S. Government Printing Office. Washington, DC.
30. 30. HURT, R.D. & C.R. ROBERTSON. 1998. Prying open the door to the tobacco industry's secrets about nicotine. JAMA 280: 1173-1181.
31. 31. BATES, C., G.N. CONNOLLY & M. JARVIS. 1999. Tobacco Additives. Action on Smoking and Health. London.
32. 32. STRAIN, E.C. & M.L. STITZER. 1999. Methadone Treatment for Opioid Dependence. Johns Hopkins University Press. Baltimore, MD.
33. 33. SEE, R.E., J.W. GRIMM, P.J. KRUZICH & N. RUSTAY. 1999. The importance of compound stimulus in conditioned drug-seeking behavior following one week of extinction from self-administered cocaine in rats. Drug Alcohol Depend. 57: 41-49.
34. 34. WOODY, G.E., L.F. MCNICHOLAS, F. VOCCI, J.E. HENNINGFIELD, et al. 1984. Guidelines for the Development and Evaluation of Drugs for the Treatment of Psychoactive Substance Use Disorders. Food and Drug Administration Pilot Drug Evaluation Unit. Rockville, MD.
35. 35. FULCO, C.E., C.T. LIVERMAN & L.E. EARLEY, Eds. 1995. Development of Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. National Academy Press. Washington, DC.
36. 36. HENNINGFIELD J.E. & C.R. HARTEL. 1999. Scientific basis for tobacco policy: nicotine research travails. In Drug Abuse: Origins and Interventions. M.D. Glantz & C.R. Hartel, Eds. :431-446. American Psychological Association. Washington, DC.
37. 37. HENNINGFIELD, J.E., R.V. FANT, S. SHIFFMAN & J. GITCHELL. 2000. Tobacco dependence: scientific and public health basis of treatment. Econ. Neurosci. 2: 42-46.